Abstract Details

Title A Phase II Trial to Assess the Efficacy, Safety and Feasibility of 20% Subcutaneous Immunoglobulin in Patients with Myasthenia Gravis Exacerbation - Interim Analysis of Safety and Feasibility

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) (-)

Poster/Presentation
Number 175

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Derrick Blackmore (University of Alberta Hospital)	No disclosure on file
Zaeem A. Siddiqi, MD, PhD (University of Alberta Hospital)	Dr. Siddiqi has nothing to disclose.

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��